-+ 0.00%
-+ 0.00%
-+ 0.00%

Johnson & Johnson says ICOTYDE sustains psoriasis skin clearance through 2 years in Phase 3 ICONIC-TOTAL study

PUBT·10/02/2026 10:01:07
Listen to the news
Johnson & Johnson says ICOTYDE sustains psoriasis skin clearance through 2 years in Phase 3 ICONIC-TOTAL study
  • Johnson & Johnson disclosed new two-year Phase 3 ICONIC-TOTAL results for ICOTYDE (icotrokinra) in high-impact plaque psoriasis.
  • Results were already presented as a late-breaking oral presentation at the European Academy of Dermatology and Venereology Congress 2026.
  • Data showed durable skin clearance in difficult-to-treat areas, supporting ICOTYDE’s positioning as a first-line systemic therapy.
  • Safety remained consistent with prior findings, with no new issues flagged over the two-year follow-up.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610020600PR_NEWS_USPR_____NY62204) on October 02, 2026, and is solely responsible for the information contained therein.